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Role of vasopressin in support of blood pressure in potassium deficient
rats. Arginine vasopressin (AVP) has been found to contribute to the
maintenance of blood pressure (BP) in the rat. Since potassium defi-
ciency results in alterations in systemic hemodynamics, the role of AVP
in the control of BP was studied after 14 to 21 days of dietary potassium
deficiency. When potassium deficient and control rats were allowed
free access to water, plasma osmolality (301.4 I vs. 293.4 3
mOsm/kg; P < 0.02) and plasma AVP (3.5 0.2 vs. 2.4 0.2 pg/mI; P
< 0.02) were increased in potassium deficient animals. To determine
the role of this increase in AVP in the maintenance of BP, BP was
determined in rats made polydipsic by adding glucose to the drinking
water. In both control and potassium deficient rats, increased fluid
intake resulted in increased urine output, decreased urinary and plasma
osmolality, and a decrease in plasma AVP. While there was no change
in BP in control rats when fluid intake was increased, BP fell from 103.9
1.8 to 96 2.6 mm Hg (P < 0.05) in potassium deficient rats with
increased fluid intake. To confirm that the decrease in plasma AVP
caused the decrease in BP in potassium deficient rats, an AVP pressor
antagonist was employed. Following the administration of the AVP
pressor antagonist, there was no change in BP in control animals. In
contrast, BP fell from 104.3 1.9 to 98.3 2.5 mm Hg; P < 0.05 in
potassium deficient rats. In addition, vasopressin infusion in potassium
deficient rats with suppressed endogenous plasma AVP resulted in the
restoration of BP to that observed in potassium deficient rats with an
intact vasopressin system. In summary, potassium deficiency results in
an elevation in plasma AVP as a consequence of hyperosmolality. Since
maneuvers which decreased either the content or action of AVP
resulted in a decrease in BP in potassium deficient rats and since
vasopressin infusion resulted in restoration of MAP in potassium
deficient rats with suppressed endogenous plasma AVP, we conclude
that AVP is important in the support of BP in the potassium deficient
conscious rat.
Role de Ia vasopressine dans le maintien de Ia pression artérielle chez
des rats carencés en potassium. II a été montré que l'arginine vasopres-
sine (AVP) contribue au maintien de Ia pression artérielle (BP) chez Ic
rat. Puisque Ia carence en potassium entraine des alterations de
l'hemodynamique systCmique, Ic role de l'AVP dans le contrOle de Ia
BP a été étudié aprCs 14 a 21 jours de carence potassique alimentaire.
Quand des rats carencés en potassium et contrôles buvaient librement
de l'eau, I'osmolalité plasmatique (301.4 I contre 293.4 3
mOsm/kg; P < 0.02) et l'AVP plasmatique (3.5 0.2 contre 2.4 0.2
pg/mI; P < 0.02) étaient élevées chez les animaux carencCs en potassi-
um. Afin de determiner le role de cette augmentation de l'AVP dans Ic
maintien de Ia BP, Ia BP a été déterminée chez des rats rendus
polydipsiques en ajoutant du glucose a l'eau de boisson. Chez les rats
contrOles et déficients en potassium, I'augmentation de l'apport liqui-
dien a entrainé une augmentation du debit urinaire, une diminution de
I'osmolalité urinaire et plasmatique et une diminution de l'AVP plasma-
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tique. Alors qu'il n'y avait pas de modification de BP chez les rats
contrOles lorsque I'apport liquidien était augmente, BP a diminuC de
103.9 1.8 a 96 2.6 mm Hg (P < 0.05) chez les rats carencés en
potassium lorsque l'apport liquidien a été augmente. Afin de confirmer
que Ia diminution de I'AVP plasmatique était a l'origine de Ia diminution
de BP chez les rats carencés en potassium, un antagoniste de l'effet
pressifde I'AVP a eté utilisé. Aprés I'administration de l'antagoniste de
I'effet pressif de I'AVP, il ny a pas eu de modification de BP chez les
animaux contrOles. A l'opposé, BP a chute de 104.3 1.9 a 98.3 2.5
mm Hg; P < 0.05 chez les rats carencés en potassium. En outre, Ia
perfusion de vasopressine chez des rats carencés en potassium avec
AVP plasmatique endogene supprimée a entrainé Ia restauration de Ia
BP a Ia valeur observée chez des rats déficients en potassium avec un
système vasopressine intact. En résumé Ia carence en potassium
entraine une élévation de l'AVP plasmatique, consequence de l'hyper-
osmolalite. Puisque que les manoeuvres diminuant soit Ic contenu soit
l'action de l'AVP ont entrainé une diminution de Ia BP chez des rats
carencCs en potassium, et que Ia perfusion de vasopressine a restauré Ia
MAP chez des rats déficients en potassium avec une AVP plasmatique
endogène supprimée, nous concluons que I'AVP est importante pour Ic
maintien de Ia BP chez le rat éveillé carencé en potassium.
Chronic potassium deficiency causes marked changes in
hemodynamics in the conscious rat. Although peripheral vascu-
lar resistance (PVR) decreases 30%, there is only a slight
decrease (10%) in mean arterial pressure (MAP) because of an
increase in cardiac output [1]. The decrease in PVR in potassi-
um deficient rats is of particular interest since it occurs in the
setting of a threefold increase in plasma renin activity [2]. This
observation suggests that the pressor effect of angiotensin II is
blunted in potassium deficiency [3] and raises the possibility
that other pressor hormones might contribute to the mainte-
nance of peripheral vascular resistance, and therefore MAP, in
potassium deficient animals.
Arginine vasopressin (AVP) is a pressor hormone which may
contribute to the increase in MAP in some forms of hyperten-
sion [4—6]. In addition, AVP has recently been demonstrated to
contribute to the maintenance of MAP during hemorrhage [5—9]
and water deprivation [10, 11]. The increase in AVP following
these maneuvers is the result of nonosmotic and osmotic
release of AVP, respectively. Since potassium deficiency is
associated with a renal concentrating defect [12] (osmotic
stimulus) as well as a decrease in PVR and MAP (nonosmotic
stimulus), it might be anticipated that plasma AVP would be
elevated in the potassium deficient animal. The purpose of the
present study was to determine the role of AVP in the support
of blood pressure in the conscious potassium deficient rat.
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Methods
Studies were performed in Sprague-Dawley rats (Charles
River Breeding Laboratories, Wilmington, Massachusetts)
weighing 190 to 250 g at the initiation of the study. Experimental
animals were fed a potassium deficient diet (ICN Nutritional
Biochemicals, Cleveland, Ohio) containing Na, 150 mEq/kg; K,
10 mEq/kg; Cl, 620 mEqlkg; Ca, 235 mEqlkg; P04, 1.8 glkg; and
Mg, 330 mEq/kg for 14 to 21 days. Control rats were fed an
identical diet to which has been added KCI, K2HPO4, and
KH2PO4 to yield a final content of Na, 160 mEq/kg; K, 240
mEq/kg; Cl, 740 mEq/kg; Ca, 210 mEq/kg; P04 5.9 g/kg; and
Mg, 339 mEqlkg. Rats had free access to food and water.
Effects of potassium deficiency on MAP and plasma AVP
To obtain hemodynamic measurements, animals were anes-
thetized with ether, and polyethylene catheters (PE-50) were
placed in the femoral artery and vein for direct arterial pressure
monitoring and blood sampling, respectively. During surgery
(10 mm) rats were given volume replacement of 0.5% body
weight with isotonic saline. Following surgery, animals were
placed in restraining cages and allowed to recover in a quiet
room for a minimum of 60 mm. MAP was then measured using a
Bell and Howell pressure transducer (type 4-327-I) and Gilson
polygraph (Gilson Medical Electronics, Middletown, Wiscon-
sin). After MAP determinations, blood was obtained for deter-
mination of potassium and osmolality. For determination of
plasma vasopressin and renin activity, additional groups of rats
were placed on similar dietary protocols and then sacrificed by
decapitation.
Plasma and urine sodium and potassium were determined by
flame photometer (Instrumentation Laboratory, model 343,
Lexington, Massachusetts) and plasma and urine osmolality by
freezing point depression (Advanced Instruments Osmometer,
model 3W, Neeham Heights, Massachusetts). Plasma AVP and
renin activity were measured by radioimmunoassay [13, 14].
Effects of increased fluid intake on MAP and plasma AVP
To study the role of AVP in support of MAP, AVP release
was suppressed by increasing fluid intake accomplished
through the addition of glucose to the drinking water to stimu-
late taste. Potassium deficient rats rapidly increased fluid intake
when 2.5% glucose was added to the drinking water for 2 days.
Control rats were more resistant to attempts to stimulate thirst.
To cause significant increases in fluid intake, control rats were
given 5% glucose in the drinking water for 7 to 8 days. During
the period of glucose water feeding, rats were individually
housed in metabolic cages which permitted the separation of
urine and feces. Rats were accepted for further study only if
water intake was increased by more than 80%. For comparison,
control and potassium deficient rats that drank water were also
studied under metabolic conditions. Measurements of food and
fluid intake and urine output were made for each 24-hr period.
Aliquots of urine samples were obtained for the measurement of
sodium, potassium, and osmolality. In addition, all urine
samples were checked for the presence of glucose by a glucose
oxidase dipstick method (Clinistix, Ames Company, Elkhart,
Indiana). No animal in any group developed glycosuria.
At the end of this period, MAP was measured as described
above. Samples of blood were then obtained for measurement
of potassium and osmolality. For determination of plasma
vasopressin and renin activity, additional groups of rats were
placed on similar dietary protocols and then sacrificed by
decapitation.
Effects of AVP pressor antagonist
Further studies of the role of AVP in blood pressure support
were performed with the use of an antagonist of the pressor
action of vasopressin, [1-(f3-mercapto-/3, /3-cyclopentamethyl-
enepropionic acid), 2-(0-methyl) tyrosine] arginine vasopressin
[d(CH2)5 Tyr(Me) AVP] [15J. To demonstrate that the AVP
antagonist was effective in the dose employed, preliminary
studies were performed in six control rats. The pressure re-
sponse to 10 mU exogenous vasopressin (Pitressin, Parke
Davis, Detroit, Michigan) was determined before and after the
administration of the AVP antagonist given as an intravenous
bolus of 10 pg/kg. After determining the efficacy of the AVP
antagonist, the drug was administered to ten control and six
potassium deficient rats following surgical preparation as de-
scribed above. For these studies, rats had received their usual
water intake until the time of study. Additional studies using the
AVP antagonist were performed in potassium deficient rats
with suppressed vasopressin levels (see below) secondary to
increased fluid intake as described above. For these studies, the
AVP antagonist was administered to four potassium deficient
rats drinking 2.5% glucose.
Effects of vasopressin infusion in potassium deficient rats
with increased fluid intake
In a final group of studies vasopressin was infused into
potassium deficient rats with suppressed AVP levels secondary
to increased fluid intake. For these studies seven potassium
deficient rats were prepared as described in the section on the
effects of increased fluid intake on MAP. MAP was determined
and vasopressin was infused at 8 U/min/l00 g body weight for
1 hr (1 cc total volume) after which MAP was recorded and
blood was obtained for plasma AVP determination. In prelimi-
nary studies we had determined that this dose of vasopressin
resulted in plasma AVP levels of 3 to 4 pg/mI. For comparison,
MAP and plasma AVP levels were also determined in five
potassium deficient rats with usual fluid intake which had been
prepared for surgery and infused for 1 hr with the same volume
of 0.45 M saline as that utilized in the vasopressin infusion
group.
Results are expressed as mean SE. Statistical comparisons
were made by the unpaired t test or one-way analysis of
variance with Duncan's multiple range test [16].
Results
Effects of potassium deficient diet on MAP and plasma AVP
At the time of study, plasma potassium was 3.95 0.3
mEq/liter in control rats and 2.24 0.32 mEq/liter in potassium
deficient rats (P < 0.001). Previous studies from our laboratory
using the identical diet have shown significant decreases in
muscle and kidney potassium content after 14 to 21 days of
dietary potassium deficiency [I, 2J.
Table I and Figure 1 demonstrate the effect of potassium
deficiency on plasma osmolality and AVP. Since not all deter-
minations could be performed in each animal, the number of
rats available for each determination is indicated. Plasma
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Table 1. Effect of potassium deficiency on plasma osmolality (P0,,,)
Final 24-hr
Intake
ml
Urine
volume
ml
Uosm POm
mOsmlkg mOsmlkg
Control
N
43.2 1.5
12
23.7 1.5
12
1840 70 293.4 3
12 10
Control with in-
creased fluid in-
take
N
l15 5.8
8
76.8 7
8
256 41 292.1 1.2
8 8
Potassium deficienta
N
67.7 47b
13
55 45b
13
605 51° 301.4 P'
13 II
Potassium deficient
with increased
fluid intake'
N
118 11.4°
12
l02.7 9.7°
12
297 30°290 2.4b
12 5
Control versus potassium deficient rats, P < 0.05b, P < 0.001° by
one-way analysis of variance.
Potassium deficient versus potassium deficient with increased fluid
intake, P < 0.05b, P < 0.Ole, P < 0.001° by one-way analysis of
variance.
Fig. 1. Effect of potassium deficiency on plasma arginine vasopressin
(AVP). Open bars represent usual fluid intake; hatched bars represent
increased fluid intake produced by watering with glucose solutions.
Parentheses indicate the number of animals studied in each group.
osmolality was increased in potassium deficient rats (301.4 1
mOsm/kg in potassium deficiency vs. 293.4 3 mOsm/kg in
control; P < 0.02; Table 1). This increase in plasma osmolality
was associated with a 46% increase in plasma AVP (3.5 0.2
pg/mi in potassium deficient rats vs. 2.4 0.2 pg/mI in control
rats; P < 0.02). Despite this increase in plasma AVP in
Fig. 2. Effect of increasing fluid intake on mean arterial pressure
(MAP). Open bars represent usual fluid intake; hatched bars represent
increased fluid intake. Parentheses indicate the number of animals
studied in each group.
potassium deficiency, basal MAP was only 103.9 1.8 mm Hg
in potassium deficient rats compared to 109.5 I .3 mm Hg in
control rats (P < 0.05).
Effects of increased fluid intake on mean arterial pressure
and plasma AVP
To study the role of AVP in blood pressure support and to
determine whether or not the increase in plasma AVP was
caused by the increase in plasma osmolality, fluid intake was
increased in control and potassium deficient animals. Control
rats drinking water (usual fluid intake) had fluid intake and urine
volume and osmolality as shown in Table 1. In contrast, control
rats drinking 5% glucose (increased fluid intake) had significant-
ly greater fluid intake and urine output. This was associated
with a lower plasma and urinary osmolality (Table 1) and a
decrease in plasma vasopressin (Fig. 1). Mean arterial pressure
was the same in control rats with usual fluid intake (109.4 2.6
mm Hg) and those with increased fluid intake (111.7 4.1 mm
Hg).
As shown in Table 1, potassium deficient rats drinking 2.5%
glucose (increased fluid intake) also had significantly greater
fluid intake and urine output and significantly lower urine and
plasma osmolality than potassium deficient rats drinking water
(usual fluid intake). Moreover, in association with the decrease
in plasma osmolality, plasma AVP decreased to levels which
were similar to control rats with increased fluid intake: I .05
0.4 pg/mI (Fig. 1). This decrease in plasma AVP levels was
associated with a decrease in MAP in potassium deficient rats:
103.9 1.8mm Hg during usual fluid intake versus 96 2.6mm
Hg after increased fluid intake; P < 0.05 (Fig. 2). Since there
was no increase in osmolar excretion (Usmv) or change in
sodium balance or plasma renin activity in glucose-drinking
potassium deficient rats (Table 2), it is likely that the decrease
in MAP was caused by the decrease in plasma AVP.
95
P C 0.05
Control Potassium
deficient
Vasopressin in potassium deficiency 345
Table 2. Effect of glucose drinking on solute excretion, sodium
balance, and plasma renin in potassium deficient rats
U0,,,V
mOsmI48°
Net Na
balance
p.Eq148°
PRA
ng/ml/hr
Potassium deficient
N = 8 59.5 2.6 1190 375 11.48 2.2
Potassium deficient drinking
2.5% glucose
N = 6 51.0 2.0
P<0.05
1260 332
NS
10.48 1.4
NS
Abbreviations: NS, no significant difference; PRA, plasma renin
activity.
Effects of AVP pressor antagonist on mean arterial pressure
To confirm that a decrease in plasma AVP results in a
decrease in MAP in potassium deficient rats, further studies
were performed with an AVP pressor antagonist. In the dose
used, the AVP antagonist completely blocked the pressor
response to 10 mU exogenous vasopressin in normal rats. MAP
increased 39.6 3.3mm Hg after AVP alone, but only 0.8 1.2
mm when AVP was given after the antagonist. Administration
of the AVP antagonist did not produce change in blood pressure
in control rats (Fig. 3). In contrast, administration of the AVP
antagonist produced a significant fall in MAP in potassium
deficient rats, from 104.3 1.9mm Hg to 98.3 2.5 mm Hg; P
<0.05). Furthermore, when the antagonist was administered to
potassium deficient rats with suppressed vasopressin levels
secondary to increased fluid intake, there was no further fall in
blood pressure (Fig. 4).
Effects of vasopressin infusion in potassium deficient rats
with increased fluid intake
To further determine the role of AVP to support MAP in
potassium deficiency, vasopressin was infused into potassium
deficient rats with suppressed plasma AVP levels secondary to
increased fluid intake. Figure 5 demonstrates that when vaso-
pressin was infused to provide plasma AVP levels (3.26 0.3
pg/mi) comparable to potassium deficient rats with the usual
fluid intake (3.64 0.6 pg/mI), MAP increased by 8.5 1,1 mm
Hg and was not different than potassium deficient rats with
usual fluid intake.
Discussion
In the present study, we investigated the role of arginine
vasopressin in the support of blood pressure in the chronic
potassium deficient rat. We utilized maneuvers which sup-
pressed both the release of AVP and the action of AVP on
vascular smooth muscle. Both approaches provided evidence
that vasopressin supports blood pressure in the conscious
potassium deficient rat.
Potassium deficiency resulted in an elevation of plasma
vasopressin levels. There are at least four possible mechanisms
by which this could have occurred: (1) potassium deficiency
results in a decrease in PVR and MAP and the subsequent
nonosmotic stimulation of AVP release [17]; (2) potassium
deficiency results in an increase in plasma renin activity and All
Fig. 3. Effect of the A VP pressor antagonist d(CH2) Tyr(Me)A VP on
MAP. Open bars represent MAP before administration of the AVP
antagonist; hatched bars represent MAP after administration of the
antagonist. Parentheses indicate the number of animals studied in each
group.
which resulted in AVP release [18]; (3) potassium deficient rats
have a renal concentrating defect [12] which results in an
increase in plasma osmolality and enhanced AVP release; and
(4) potassium deficiency per se might directly stimulate AVP
release. The results suggest that the increase in AVP was
mediated by an osmolar stimulus. In this regard, potassium
deficient rats had an increase in plasma osmolality which was
corrected by increasing the fluid intake of these animals.
Moreover, in association with the decrease in plasma osmolali-
ty of glucose-drinking potassium deficient rats, AVP decreased
to levels comparable to control rats. This decrease in AVP
occurred despite continued potassium deficiency and hyperren-
inemia, and was associated with a further decrease in MAP, a
hemodynamic factor which would be expected to further in-
crease AVP levels. Thus, while there are several possible
mechanisms for the increase in plasma AVP in potassium
deficiency, it is likely that the increase in AVP is a consequence
of hyperosmolality resulting from the renal concentrating defect
[12] associated with chronic potassium deficiency.
The role of the increase in vasopressin levels in potassium
deficiency was first studied by suppressing AVP release. To
accomplish this, animals were induced to increase their fluid
intake by adding glucose to their drinking water (Table 1).
Following increased fluid intake, AVP decreased in both con-
trol and potassium deficient rats. While AVP levels fell in
control rats, there was no change in mean arterial pressure (Fig.
2). In marked contrast, however, suppression of plasma AVP
levels in potassium deficient rats resulted in a significant
decrease in MAP (Fig. 2). Furthermore, the decrease in MAP in
potassium deficient rats could not be explained by changes in
either sodium balance or plasma renin activity. These studies
demonstrate, therefore, that vasopressin supports the MAP of
potassium deficient, but not control, rats.
To further investigate the role of vasopressin in the support of
95.
NS
P< 0.05
Control Potassium
rlpfinipnt
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Fig. 4. Effect of A VP pressor antagonist on MAP in potassium deficient
rats with suppressed vasopressin levels. AVP was suppressed by adding
2.5% glucose to the drinking water (open bars). Hatched bars represent
MAP in potassium deficient rats with suppressed AVP levels after
administration of the AVP antagonist. Parentheses indicate the number
of animals studied in each group.
blood pressure in potassium deficiency, an antagonist of the
pressor action of AVP [d(CH2)5 Tyr(Me)AVPJ was employed.
As has been demonstrated by other investigators [10], adminis-
tration of the AVP antagonist did not produce change in MAP in
control rats (Fig. 3). In contrast, administration of the AVP
antagonist produced a decrease in blood pressure in potassium
deficient rats similar in magnitude to the decrease in blood
pressure observed when AVP release was suppressed by in-
creasing fluid intake. In addition, when AVP levels were
suppressed in potassium deficient rats by increasing their fluid
intake, the AVP antagonist had no additional depressor effect.
Thus, when either the content or the action of AVP is de-
creased, there is a decrease in MAP in potassium deficient, but
not control, animals.
In the final group of studies vasopressin was administered to
potassium deficient rats in which endogenous plasma AVP
levels had been suppressed by inducing increased fluid intake.
When plasma AVP levels were rendered comparable to potassi-
um deficient rats with usual fluid intake, MAP was restored to
the levels observed in potassium deficient rats with usual fluid
intake (Fig. 5).
These three complementary studies suggest that vasopressin
plays an important role in the support of blood pressure in the
potassium deficient rat. Of interest is the fact that these studies
demonstrate that vasopressin supports blood pressure in the
normovolemic state. In other studies, the administration of an
AVP pressor antagonist has been found to lower MAP following
acute hemorrhage [91, and after 24 to 40 hr of water restriction
[10, 11], maneuvers which would be anticipated to decrease
circulating blood or plasma volume, respectively. In contrast,
the potassium deficient rat is in positive sodium balance [19]
and has an increased plasma volume [I].
A surprising observation in the present study was that AVP
antagonism lowered MAP in potassium deficient rats despite
plasma AVP levels which are generally not felt to be within the
range of pressor activity of this hormone [20, 21]. Although the
present study does not provide an explanation for this observa-
tion, two possibilities seem likely, Several studies have demon-
strated that relatively modest elevations of AVP increase blood
pressure in the absence of a functional autonomic nervous
system [22, 23]. While the status of the autonomic nervous
system has not been assessed in the potassium deficient rats,
there is evidence that potassium deficiency results in autonomic
insufficiency in potassium deficient patients [24]. Moreover, it
is possible that even small increases in AVP are important to
support MAP in the vasodilated potassium deficient rat since
these animals are markedly resistant to another major pressor
hormone, angiotensin II [3]. Further studies will be required to
explore these possibilities.
The absolute magnitude of mean blood pressure fall after
vasopressin removal or antagonism was moderate. However,
even in the presence of AVP, MAP was decreased in potassium
deficient rats. In the absence of AVP, MAP fell to levels less
than 100 mm Hg. Since the rat begins to lose its ability to
autoregulate renal blood flow below 100 mm Hg [25], any
decrease in MAP below this value might be expected to
compromise renal function. This is particularly important in
potassium deficiency since renal blood flow is only 50% of the
value obtained in normal animals [I].
In summary, potassium deficiency in the rat results in a
decrease in mean arterial pressure and an increase in plasma
osmolality and plasma AVP. Following increased fluid intake,
both plasma osmolality and AVP can be normalized. In potassi-
um deficient, but not control, rats reduction of the plasma level
of vasopressin or antagonism of its action results in a further
110
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Fig. 5. The effect ofAVP infusion on MAP in potassium deficient rats
with increased fluid intake. Potassium deficient rats with increased fluid
intake (left bar) were infused with AVP (middle bar) and compared to
potassium deficient rats with usual fluid intake (right bar). Parentheses
indicate the number of animals studied in each group.
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decrease in mean arterial pressure. In potassium deficient rats
with suppressed endogenous vasopressin levels, vasopressin
infusion results in restoration of MAP to values observed in
potassium deficient rats with an intact vasopressin system. We
conclude that an increase in plasma osmolality mediates the
increase in AVP levels and that arginine vasopressin contrib-
utes support of systemic arterial pressure in the conscious
potassium deficient rat.
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